Kawano, Noriaki
Kimura, Shinya
Miura, Masatomo
Tochigi, Taro
Nakaike, Takashi
Yamashita, Kiyoshi
Mashiba, Koichi
Kikuchi, Ikuo
Takahashi, Naoto
Article History
Received: 19 March 2021
Revised: 24 June 2021
Accepted: 29 June 2021
First Online: 18 August 2021
Declarations
:
: The authors (Noriaki Kawano, Masatomo Miura, Taro Tochigi, Takashi Nakaike, Kiyoshi Yamashita, Koichi Mashiba, Ikuo Kikuchi) have no conflicts of interest to declare. Shinya Kimura reports that he has received speaker’s fees from Novartis Pharmaceuticals, Grants and speaker’s fees from Bristol Myers Squibb, Pfizer and Otsuka Pharmaceutical, Grants from Kyowa Hakko Kirin, Astellas Pharma, Chu-gai Pharmaceutical, Asahi Kasei Pharma, Nippon Shinyaku, Ono Pharmaceutical, Eisai Pharmaceuticals, Taiho, Pharmaceutical, Ohara pharmaceutical and Takeda outside of the submitted work. Naoto Takahashi reports that he has received Grants and speaker’s fees from Novartis Pharmaceuticals, speaker’s fees from Bristol Myers Squibb, Grants and speaker’s fees from Pfizer, Grants and speaker’s fees from Otsuka Pharmaceutical, Grants from Kyowa Hakko Kirin, Grants from Astellas Pharma, Grants from Chugai Pharmaceutical, Grants from Asahi Kasei Pharma, Grants from Ono Pharmaceutical, and Grants from Eisai Pharmaceuticals, outside of the submitted work. The remaining authors declare that they have no conflicts of interest.